abaloparatide

H.C. Wainwright & Co.'s Carol Ann Werther initiated Radius Health Inc (NASDAQ: RDUS) at Buy with a $55.00 price target. The company's lead product candidate is abaloparatide (ABL), which is currently under review in Europe and the United States. "We expect launches in 4Q16 and 1Q17," said...